Microlax (Sodium Citrate, Sorbitol (E420), Sodium Lauryl Sulfoacetate)

Sodium citrate, together with sorbitol and sodium lauryl sulfoacetate, creates an osmotic gradient that draws water into the colon. The increased fluid softens the fecal mass, while the surfactant irritates the rectal lining, prompting peristaltic contractions. This combined effect facilitates quick evacuation of stool without significant systemic absorption.

The appropriate dose of Microlax is determined by the prescribing healthcare professional based on the patient’s age, condition, and clinical need. Typically a single enema is administered rectally, and the patient is advised to retain the solution for a short period to allow the laxative effect. Repeat dosing should follow medical guidance.

Safety data for Microlax in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider. Women who are pregnant or nursing should discuss alternative options and obtain professional advice before use.

To place an order, submit an enquiry on the Microlax product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including any temperature requirements—and assists with import documentation.

Compared with oral stimulant laxatives, Microlax acts locally in the rectum, producing a faster onset of action and fewer systemic side effects. Unlike bulk‑forming agents, it does not require dietary fiber intake. Its osmotic mechanism is similar to other rectal enemas, but the inclusion of a surfactant offers additional mucosal stimulation, making it particularly effective for rapid bowel cleansing.

Microlax should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Keep out of reach of children and do not use the solution after the expiration date printed on the packaging.

Microlax is administered rectally as a single‑dose enema. The patient lies on their side with knees drawn toward the chest, inserts the applicator tip gently into the rectum, and releases the solution. After administration, the patient should remain in the same position for a few minutes to allow the enema to work, then proceed to the toilet to evacuate the bowels.

The most serious risks include severe abdominal pain, rectal bleeding, and rare allergic reactions such as rash, swelling, or difficulty breathing. In patients with electrolyte disorders, excessive fluid loss may lead to imbalance. Anyone experiencing intense pain, persistent bleeding, or signs of an allergic response should seek immediate medical attention.

Microlax is contraindicated in individuals with known or suspected intestinal obstruction, severe inflammatory bowel disease flare, or hypersensitivity to any of its ingredients. It should also be avoided in patients with significant electrolyte disturbances unless supervised by a clinician. Children, the elderly, and pregnant or breastfeeding women should use the product only under medical advice.